Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 313

1.

Recovery of central memory and naive peripheral T cells in Follicular Lymphoma patients receiving rituximab-chemotherapy based regimen.

Milcent B, Josseaume N, Petitprez F, Riller Q, Amorim S, Loiseau P, Toubert A, Brice P, Thieblemont C, Teillaud JL, Sibéril S.

Sci Rep. 2019 Sep 17;9(1):13471. doi: 10.1038/s41598-019-50029-y.

2.

Presence of T cells directed against CD20-derived peptides in healthy individuals and lymphoma patients.

Milcent B, Josseaume N, Riller Q, Giglioli I, Rabia E, Deligne C, Latouche JB, Hamieh M, Couture A, Toutirais O, Lone YC, Jeger-Madiot R, Graff-Dubois S, Amorim S, Loiseau P, Toubert A, Brice P, Thieblemont C, Teillaud JL, Sibéril S.

Cancer Immunol Immunother. 2019 Sep 7. doi: 10.1007/s00262-019-02389-7. [Epub ahead of print]

PMID:
31494742
3.

Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087.

Chen R, Zinzani PL, Lee HJ, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Lin J, Kim E, Nahar A, Balakumaran A, Moskowitz CH.

Blood. 2019 Oct 3;134(14):1144-1153. doi: 10.1182/blood.2019000324. Epub 2019 Aug 13.

PMID:
31409671
4.

Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study.

Zinzani PL, Santoro A, Gritti G, Brice P, Barr PM, Kuruvilla J, Cunningham D, Kline J, Johnson NA, Mehta-Shah N, Manley T, Francis S, Sharma M, Moskowitz AJ.

J Clin Oncol. 2019 Aug 9:JCO1901492. doi: 10.1200/JCO.19.01492. [Epub ahead of print]

PMID:
31398081
5.

Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study.

Bachy E, Seymour JF, Feugier P, Offner F, López-Guillermo A, Belada D, Xerri L, Catalano JV, Brice P, Lemonnier F, Martin A, Casasnovas O, Pedersen LM, Dorvaux V, Simpson D, Leppa S, Gabarre J, da Silva MG, Glaisner S, Ysebaert L, Vekhoff A, Intragumtornchai T, Le Gouill S, Lister A, Estell JA, Milone G, Sonet A, Farhi J, Zeuner H, Tilly H, Salles G.

J Clin Oncol. 2019 Jul 24:JCO1901073. doi: 10.1200/JCO.19.01073. [Epub ahead of print]

PMID:
31339826
6.

Challenges in the diagnosis of primary cutaneous CD30+ anaplastic large-cell lymphoma.

Dobos G, Battistella M, Jouenne F, Mourah S, Vignon-Pennamen MD, Ram-Wolff C, Herms F, Dauendorffer JN, Rivet J, Cayuela JM, Bouaziz D, Brice P, Lebbé C, Bagot M, de Masson A.

Br J Dermatol. 2019 Jul 6. doi: 10.1111/bjd.18328. [Epub ahead of print] No abstract available.

PMID:
31278742
7.

Efficacy and safety of brentuximab vedotin plus bendamustine in advanced-stage primary cutaneous T-cell lymphomas.

Dumont M, Ram-Wolff C, Roelens M, Brice P, Peffault de Latour R, Battistella M, Madelaine I, Delyon J, Herms F, Bouaziz JD, Moins-Teisserenc H, Lebbé C, Bagot M, de Masson A.

Br J Dermatol. 2019 Jun 17. doi: 10.1111/bjd.18215. [Epub ahead of print] No abstract available.

PMID:
31206589
8.

Impact of cancer chemotherapy before ovarian cortex cryopreservation on ovarian tissue transplantation.

Poirot C, Fortin A, Lacorte JM, Akakpo JP, Genestie C, Vernant JP, Brice P, Morice P, Leblanc T, Gabarre J, Delmer A, Badachi Y, Drouineaud V, Gouy S, Chalas C, Egels S, Dhédin N, Touraine P, Dommergues M, Lebègue G, Wolf JP, Capron F, Lefebvre G, Boissel N; CAROLéLISA Cooperative Group.

Hum Reprod. 2019 Jun 4;34(6):1083-1094. doi: 10.1093/humrep/dez047.

PMID:
31116405
9.

Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation.

Manson G, Mear JB, Herbaux C, Schiano JM, Casasnovas O, Stamatoullas A, Deau B, Schmitt A, Garnier G, Regny C, Bouabdallah K, Moles-Moreau MP, Ghesquieres H, Tempescul A, Dulery R, Nicolas-Virelizier E, Delmer A, Borel C, Chauchet A, Damotte D, Dercle L, Brice P, Houot R; LYSA.

Eur J Cancer. 2019 Jul;115:47-56. doi: 10.1016/j.ejca.2019.04.006. Epub 2019 May 10.

PMID:
31082693
10.

Romidepsin is an effective and well-tolerated therapy in CD3-CD4+ lymphocyte-variant hypereosinophilic syndrome: A case report.

Baulier G, Asli B, Galicier L, Fieschi C, Brice P, Malphettes M.

J Allergy Clin Immunol Pract. 2019 May 10. pii: S2213-2198(19)30443-X. doi: 10.1016/j.jaip.2019.04.039. [Epub ahead of print] No abstract available.

PMID:
31078759
11.

Brentuximab vedotin as a bridge to allogeneic stem-cell transplantation for refractory or relapsing patients with CD30 positive anaplastic or T-cell non-Hodgkin lymphomas: a study on behalf of the SFGM-TC.

Garciaz S, Loschi M, De Masson A, Biard L, Mercier M, Tomowiak C, Delage J, Labussiere-Wallet H, Sibon D, Cassuto O, Borel C, Cornillon J, Nimubona S, Charbonnier A, Brice P, Socié G, Bouabdallah R, de Latour RP, de Fontbrune FS.

Leuk Lymphoma. 2019 Apr 24:1-4. doi: 10.1080/10428194.2019.1599112. [Epub ahead of print] No abstract available.

PMID:
31014144
12.

Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma.

von Tresckow B, Fanale M, Ardeshna KM, Chen R, Meissner J, Morschhauser F, Moskowitz C, Zinzani PL, Giezek H, Balakumaran A, Vo TT, Raut M, Brice P.

Leuk Lymphoma. 2019 Apr 23:1-7. doi: 10.1080/10428194.2019.1602262. [Epub ahead of print]

PMID:
31012356
13.

PET-guided, BEACOPPescalated therapy in advanced Hodgkin lymphoma - Authors' reply.

Casasnovas RO, Bouabdallah R, Brice P, Lazarovici J, Ghesquieres H, Stamatoullas A, Berriolo-Riedinger A, Fornecker LM, André M, Meignan M.

Lancet Oncol. 2019 Apr;20(4):e190. doi: 10.1016/S1470-2045(19)30156-1. No abstract available.

PMID:
30942177
14.

Unconventional immune-related phenomena observed using 18F-FDG PET/CT in Hodgkin lymphoma treated with anti PD-1 monoclonal antibodies.

Dercle L, Mokrane FZ, Schiano de Colella JM, Stamatoullas A, Morschhauser F, Brice P, Ghesquières H, Casasnovas O, Chen A, Manson G, Houot R.

Eur J Nucl Med Mol Imaging. 2019 Jun;46(6):1391-1392. doi: 10.1007/s00259-019-04310-x. Epub 2019 Mar 19. No abstract available.

15.

Post-transplant outcome of ovarian tissue cryopreserved after chemotherapy in hematologic malignancies.

Poirot C, Fortin A, Dhédin N, Brice P, Socié G, Lacorte JM, Akakpo JP, Genestie C, Vernant JP, Leblanc T, Gabarre J, Delmer A, Badachi Y, Drouineaud V, Chalas C, Egels S, Touraine P, Dommergues M, Lebègue G, Wolf JP, Capron F, Lefebvre G, Boissel N.

Haematologica. 2019 Aug;104(8):e360-e363. doi: 10.3324/haematol.2018.211094. Epub 2019 Feb 14. No abstract available.

16.

Anti-PD-1 immunotherapy in combination with sequential involved-site radiotherapy in heavily pretreated refractory Hodgkin lymphoma.

Quéro L, Gilardin L, Fumagalli I, Martin V, Guillerm S, Bauduceau O, Kirova YM, Hennequin C, Brice P.

Cancer Radiother. 2019 Apr;23(2):132-137. doi: 10.1016/j.canrad.2018.05.002. Epub 2019 Feb 4.

PMID:
30733172
17.

Alopecic patches of the scalp: a variant of primary cutaneous follicle centre B-cell lymphoma reported in a series of 14 cases.

de Masson A, Bouaziz JD, Ram-Wolff C, Brice P, Moulonguet I, Vignon-Pennamen MD, Herms F, Verneuil L, Rivet J, Bagot M, Battistella M.

J Eur Acad Dermatol Venereol. 2019 May;33(5):e209-e211. doi: 10.1111/jdv.15477. Epub 2019 Mar 1. No abstract available.

PMID:
30716178
18.

PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study.

Casasnovas RO, Bouabdallah R, Brice P, Lazarovici J, Ghesquieres H, Stamatoullas A, Dupuis J, Gac AC, Gastinne T, Joly B, Bouabdallah K, Nicolas-Virelizier E, Feugier P, Morschhauser F, Delarue R, Farhat H, Quittet P, Berriolo-Riedinger A, Tempescul A, Edeline V, Maisonneuve H, Fornecker LM, Lamy T, Delmer A, Dartigues P, Martin L, André M, Mounier N, Traverse-Glehen A, Meignan M.

Lancet Oncol. 2019 Feb;20(2):202-215. doi: 10.1016/S1470-2045(18)30784-8. Epub 2019 Jan 15.

PMID:
30658935
19.

L’arrivée de l’immunothérapie dans le lymphome de Hodgkin.

Gilardin L, Amorim S, Bernard S, Ravdan O, Thieblemont C, Brice P.

Bull Cancer. 2018 Dec;105 Suppl 1:S50-S58. doi: 10.1016/S0007-4551(18)30390-4. Review. French.

PMID:
30595199
20.

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.

Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Lennard A, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Iyer S, Zinzani PL, Hua Z, Little M, Rao S, Woolery J, Manley T, Trümper L; ECHELON-2 Study Group.

Lancet. 2019 Jan 19;393(10168):229-240. doi: 10.1016/S0140-6736(18)32984-2. Epub 2018 Dec 4. Erratum in: Lancet. 2019 Jan 19;393(10168):228.

PMID:
30522922

Supplemental Content

Loading ...
Support Center